UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A tumor-suppressing function in the epithelial adhesion protein Trask

Oncogene, 2012-01, Vol.31 (4), p.419-431

2012

Volltextzugriff (PDF)

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Clinical cancer research, 2010-03, Vol.16 (5), p.1373-1383

2010

Volltextzugriff (PDF)

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Clinical cancer research, 2008-12, Vol.14 (23), p.7878-7883

2008

Volltextzugriff (PDF)

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial

Breast cancer research and treatment, 2001-04, Vol.66 (3), p.239-248

2001

Volltextzugriff (PDF)

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells

Cancer research (Chicago, Ill.), 2001-04, Vol.61 (7), p.2945-2952

2001

Volltextzugriff (PDF)

Trask Loss Enhances Tumorigenic Growth by Liberating Integrin Signaling and Growth Factor Receptor Cross-Talk in Unanchored Cells

Cancer research (Chicago, Ill.), 2013-02, Vol.73 (3), p.1168-1179

2013

Volltextzugriff (PDF)

Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity to Taxol and Epothilones

Proceedings of the National Academy of Sciences - PNAS, 1998-02, Vol.95 (4), p.1369-1374

1998

Volltextzugriff (PDF)

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum

European journal of cancer (1990), 2016-07, Vol.61, p.S131-S131

2016

Volltextzugriff (PDF)

Phosphorylation of Trask by Src Kinases Inhibits Integrin Clustering and Functions in Exclusion with Focal Adhesion Signaling

Molecular and Cellular Biology, 2011-02, Vol.31 (4), p.766-782

2011

Volltextzugriff (PDF)

Disentangling multidimensional spatio-temporal data into their common and aberrant responses

PloS one, 2015-04, Vol.10 (4), p.e0121607-e0121607

2015

Volltextzugriff (PDF)

Adhesion signaling by a novel mitotic substrate of src kinases

Oncogene, 2005-08, Vol.24 (34), p.5333-5343

2005

Volltextzugriff (PDF)

A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

Clinical cancer research, 2003-04, Vol.9 (4), p.1267-1273

2003

Volltextzugriff (PDF)

The structural features of Trask that mediate its anti-adhesive functions

PloS one, 2011-04, Vol.6 (4), p.e19154-e19154

2011

Volltextzugriff (PDF)

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest

Cancer research (Chicago, Ill.), 1999-12, Vol.59 (24), p.6145-6152

1999

Volltextzugriff (PDF)

Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers

Clinical cancer research, 2009-04, Vol.15 (7), p.2311-2322

2009

Volltextzugriff (PDF)

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Clinical cancer research, 2009-09, Vol.15 (17), p.5569-5575

2009

Volltextzugriff (PDF)

Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase

Cell chemical biology, 2017-07, Vol.24 (7), p.917-917

2017

Volltextzugriff (PDF)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Cell reports (Cambridge), 2022-09, Vol.40 (10), p.111338-111338, Article 111338

2022

Volltextzugriff (PDF)

Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state

Cell cycle (Georgetown, Tex.), 2011-04, Vol.10 (8), p.1225-1232

2011

Volltextzugriff (PDF)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

Cell reports (Cambridge), 2022-02, Vol.38 (5), p.110291-110291, Article 110291

2022

Volltextzugriff (PDF)

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

Nature cell biology, 2019-06, Vol.21 (6), p.778-790

2019

Volltextzugriff (PDF)

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

Clinical cancer research, 2015-07, Vol.21 (13), p.2886-2888

2015

Volltextzugriff (PDF)

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Clinical cancer research, 2004-06, Vol.10 (12), p.4062-4067

2004

Volltextzugriff (PDF)

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers

Molecular cancer therapeutics, 2015-12, Vol.14 (12), p.2805-2817

2015

Volltextzugriff (PDF)

Regulation of inside-out β1-integrin activation by CDCP1

Oncogene, 2018-05, Vol.37 (21), p.2817-2836

2018

Volltextzugriff (PDF)

26 – 50 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(136)

Publikationsform

Sprache

Englisch
(147)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(30)
Cancer Research
(16)
Clinical Cancer Research
(12)
Oncogene
(11)
Breast Cancer Research And Treatment
(8)
Cell Cycle
(5)
Cell Reports
(4)
Biochemical Journal
(3)
European Journal Of Cancer
(3)
Molecular Cancer Therapeutics
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A tumor-suppressing function in the epithelial adhesion protein Trask

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells

Trask Loss Enhances Tumorigenic Growth by Liberating Integrin Signaling and Growth Factor Receptor Cross-Talk in Unanchored Cells

Farnesyl Transferase Inhibitors Cause Enhanced Mitotic Sensitivity to Taxol and Epothilones

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum

Phosphorylation of Trask by Src Kinases Inhibits Integrin Clustering and Functions in Exclusion with Focal Adhesion Signaling

Disentangling multidimensional spatio-temporal data into their common and aberrant responses

Adhesion signaling by a novel mitotic substrate of src kinases

A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

The structural features of Trask that mediate its anti-adhesive functions

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest

Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers

Regulation of inside-out β1-integrin activation by CDCP1

Suchergebnisse filtern